Antineoplastic combinations

A method of treating a neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of a combination comprising CCI-779 and an aromatase inhibitor, wherein either CCI-779, the aromatase inhibitor, or both are provided in subtherapeutically effective amounts.

An antineoplastic combination comprising an antineoplastic effective amount of a combination of CCI-779 and an aromatase inhibitor.

A method of treating a neoplasm in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination comprising 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.

A method of treating an estrogen receptor positive carcinoma in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination comprising CCI-779 and an aromatase inhibitor.

A method of treating an estrogen receptor positive carcinoma in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination comprising 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.

A product containing (a) CCI-779 or 42-O-(2-hydroxy)ethyl rapamycin and (b) an aromatase inhibitor as a combined preparation for simultaneous, separate or sequential use in treating a neoplasm in a mammal in need thereof.

A pharmaceutical pack containing a course of treatment of a neoplasm for one individual mammal, wherein the pack contains (a) units of CCI-779 or 42-O-(2-hydroxy)ethyl rapamycin in unit dosage form and (b) units of an aromatase inhibitor in unit dosage form.

A pharmaceutical composition useful in treating a neoplasm in a mammal in need thereof, the composition comprising (a) CCI-779 or 42-O-(2-hydroxy)ethyl rapamycin and (b) an aromatase inhibitor in combination or association with a pharmaceutically acceptable carrier.

An antineoplastic combination comprising an antineoplastic effective amount of a combination of 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.